Fentanyl transdermal absorption linked to pharmacokinetic characteristics in patients undergoing palliative care
- PMID: 20097932
- DOI: 10.1177/0091270009347872
Fentanyl transdermal absorption linked to pharmacokinetic characteristics in patients undergoing palliative care
Abstract
Delivery rates and plasma concentrations vary among patients treated with fentanyl patches. Absorption and urinary excretion characteristics of fentanyl were studied in patients undergoing palliative care. Almost 500 patches were analyzed for residual fentanyl content. Fentanyl and norfentanyl levels were determined in the urine of 50 patients. General and mixed effects linear regression models were established for the relationship between fentanyl dose rate and urinary excretion and to incorporate influencing factors. For different patch nominal dose strengths, wide but comparable variability in estimated dose rate and delivery efficiency was observed (coefficients of variation of 15% to 17%). Fentanyl delivery efficiency was 8.5% higher for patches of 25 microg/h as compared to 75 microg/h and, accordingly, 7.5% for patch application on the arm as compared to the leg. Urinary fentanyl and norfentanyl concentrations varied considerably. The general linear model revealed a positive effect of the calculated transdermal dose rate on urinary fentanyl levels, explaining 34% of the variability (P < .0001). In addition, gender (P = .04) and type of cancer pathology (P = .03) exerted significant effects on the linear model, explaining 40% and 64% of the variability, respectively. Delivery efficiency of fentanyl patches can vary substantially, possibly leading to either underdosing or overdosing.
Similar articles
-
Inter- and intra-individual variability in transdermal fentanyl absorption in cancer pain patients.Oncol Rep. 2005 Oct;14(4):1029-36. Oncol Rep. 2005. PMID: 16142368
-
A Phase III study to assess the clinical utility of low-dose fentanyl transdermal system in patients with chronic nonmalignant pain.Curr Med Res Opin. 2006 Aug;22(8):1493-501. doi: 10.1185/030079906X115540. Curr Med Res Opin. 2006. PMID: 16870074 Clinical Trial.
-
Transdermal fentanyl matrix patches Matrifen and Durogesic DTrans are bioequivalent.Eur J Pharm Biopharm. 2010 Jun;75(2):225-31. doi: 10.1016/j.ejpb.2010.02.005. Epub 2010 Feb 10. Eur J Pharm Biopharm. 2010. PMID: 20152899 Clinical Trial.
-
Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).Pain Pract. 2008 Jul-Aug;8(4):287-313. doi: 10.1111/j.1533-2500.2008.00204.x. Epub 2008 May 23. Pain Pract. 2008. PMID: 18503626
-
Transdermal therapeutic fentanyl-system (TTS-F).In Vivo. 2004 Sep-Oct;18(5):633-42. In Vivo. 2004. PMID: 15523905 Review.
Cited by
-
Does transdermal fentanyl work in patients with low BMI? Patient-reported outcomes of pain and percent pain relief in cancer patients on transdermal fentanyl.Cancer Med. 2019 Dec;8(18):7516-7522. doi: 10.1002/cam4.2479. Epub 2019 Sep 30. Cancer Med. 2019. PMID: 31568684 Free PMC article.
-
Is personal physiology-based rapid prediction digital twin for minimal effective fentanyl dose better than standard practice: a pilot study protocol.BMJ Open. 2024 Sep 24;14(9):e085296. doi: 10.1136/bmjopen-2024-085296. BMJ Open. 2024. PMID: 39317494 Free PMC article.
-
A review of factors explaining variability in fentanyl pharmacokinetics; focus on implications for cancer patients.Br J Clin Pharmacol. 2017 Feb;83(2):294-313. doi: 10.1111/bcp.13129. Epub 2016 Oct 29. Br J Clin Pharmacol. 2017. PMID: 27619152 Free PMC article.
-
Influence of aprepitant and localization of the patch on fentanyl exposure in patients with cancer using transdermal fentanyl.Oncotarget. 2018 Apr 6;9(26):18269-18276. doi: 10.18632/oncotarget.24812. eCollection 2018 Apr 6. Oncotarget. 2018. PMID: 29719604 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical